Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 19/20 | 0.65 |
| ▸ | DRD3 | P35462 | 12/20 | 0.65 |
| ▸ | DRD4 | P21917 | 5/20 | 0.58 |
| ▸ | HTR2A | P28223 | 7/20 | 0.57 |
| ▸ | HTR1A | P08908 | 4/20 | 0.57 |
| ▸ | DRD1 | P21728 | 1/20 | 0.54 |
| ▸ | FAAH | O00519 | 1/20 | 0.54 |
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3163333 | 0.93 | DRD2 (0.64) | DRD2DRD3DRD4HTR2AHTR1A | |
| SCHEMBL2201219 | 0.84 | ADAMTS5 (0.55) | DRD2DRD3DRD4HTR2AHTR1A | |
| SCHEMBL6005640 | 0.84 | HTR1A (0.62) | DRD2DRD3DRD4HTR2AHTR1A | |
| SCHEMBL3187864 | 0.83 | DRD2 (0.67) | DRD2DRD3DRD4HTR2AHTR1A | |
| SCHEMBL1491196 | 0.83 | DRD2 (0.68) | DRD2DRD3DRD4HTR2AHTR1A | |
| Hydrochloric Acid SCHEMBL3207599 | 0.82 | DRD2 (0.65) | DRD2DRD3DRD4HTR2AHTR1A | |
| SCHEMBL10759929 | 0.80 | KCNH2 (0.64) | DRD2DRD4HTR2AHTR1A | |
| SCHEMBL1491170 | 0.80 | DRD2 (0.67) | DRD2DRD3DRD4HTR2AHTR1A | |
| SCHEMBL12441074 | 0.80 | DRD2 (1.00) | DRD2DRD3DRD4HTR2AHTR1A | |
| SCHEMBL7957657 | 0.80 | DRD2 (0.49) | DRD2HTR2AHTR1ACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575185-B2 | Compositions, synthesis, and methods of utilizing quinazolinedione derivatives | REVIVA PHARMACEUTICALS, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8247420-B2 | Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents | REVIVA PHARMACEUTICALS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8207163-B2 | Compositions, synthesis, and methods of using piperazine based antipsychotic agents | REVIVA PHARMACEUTICALS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| EP-2299814-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PIPERAZINE BASED ANTIPSYCHOTIC AGENTS | Reviva Pharmaceuticals, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| WO-2010099503-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF UTILIZING QUINAZOLINEDIONE DERIVATIVES | REVIVA PHARMACEUTICALS, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20100222359-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF UTILIZING QUINAZOLINEDIONE DERIVATIVES | REVIVA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
| EP-2162135-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING QUINOLINONE BASED ATYPICAL ANTIPSYCHOTIC AGENTS | Reviva Pharmaceuticals, Inc. (US) | 2010-03-17 | — | — | EP | disclosed |
| WO-2009154993-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PIPERAZINE BASED ANTIPSYCHOTIC AGENTS | REVIVA PHARMACEUTICALS, INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| US-20090298819-A1 | Compositions, Synthesis, And Methods Of Using Piperazine Based Antipsychotic Agents | REVIVA PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| WO-2008144764-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING QUINOLINONE BASED ATYPICAL ANTIPSYCHOTIC AGENTS | REVIVA PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| US-20080293736-A1 | Compositions, Synthesis, and Methods of Using Quinolinone Based Atypical Antipsychotic Agents | REVIVA PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222359-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF UTILIZING QUINAZOLINEDIONE DERIVATIVES | GRIN2D, GRIK5, GRIK4 | DRD2 82/4885DRD3 112/4885DRD4 92/4885 |
| US-20080293736-A1 | Compositions, Synthesis, and Methods of Using Quinolinone Based Atypical Antipsychotic Agents | GRIN2D, GRIN2C, AP3D1 | DRD2 26/4885DRD3 64/4885DRD4 38/4885 |
| US-20090298819-A1 | Compositions, Synthesis, And Methods Of Using Piperazine Based Antipsychotic Agents | GRIK5, GAP43, GRIN2D | DRD2 33/4885DRD3 87/4885DRD4 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.